No profile data available.
Oculis Holding AG (OCS) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Zug, Switzerland, with about 49 full-time employees.
It reported revenue of 0 CHF for fiscal year 2025, and net income of -98.96 million CHF. Its market capitalization was $1.14 billion as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally.
Oculis Holding reported 0 CHF in revenue for fiscal year 2025.
$1.14 billion as of December 4, 2025.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Immunocore Holdings plc (IMCR), Nektar Therapeutics (NKTR), Sana Biotechnology, Inc. (SANA), Amphastar Pharmaceuticals, Inc. (AMPH).